Skip to main content
Premium Trial:

Request an Annual Quote

Alzheimer's Disease Test Firm DiamiR Awarded Additional $345K From NIA

NEW YORK — Diagnostics developer DiamiR said today that it has received an additional $345,000 in grant funding from the National Institute on Aging to develop a microRNA-based test for early-stage Alzheimer's disease.

In 2017, the Monmouth Junction, New Jersey-based company received a $2.8 million Phase IIB Small Business Innovation Research from the NIA for the test, called CogniMir. The new funding was awarded under that ongoing grant.

"Our novel diagnostic approach focuses on detecting changes in the plasma levels of microRNAs enriched in the specific brain regions affected by the disease," DiamiR CSO Samuil Umansky said in a statement. "Our goal is to provide drug developers and clinicians with a tool for identifying patients earlier, preferably before they exhibit clinical symptoms, when treatment can be more effective."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.